Dose increase augments response rate to interferon-α in chronic hepatitis C

Digestive Diseases and Sciences

Volumn 41, Issue 12 SUPPL., 1996, Pages

  Ferenci, Peter ^a   Stauber, Rudolf ^b   Propst, Albert ^b   Fiedler, Richard ^b   Müller, Christian ^b   Gschwantler, Michael ^b   Schütze, Kurt ^b   Datz, Christian ^b   Judmaier, Gerd ^b   Vogel, Wolfgang ^b   Krejs, Günther J ^b   Gangl, Alfred ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

chronic hepatitis C; dose response; interferon (2b); response rate

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 8044251508     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02087884     Document Type: Conference Paper

References (23)

1. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payeu JL, Sajus M, Costa JM, Vidaud M, Chaput JC, and the Multicenter Study Group: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 332:1457-1462, 1995
2. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC, for the Australian Hepatitis C Study Group: Interferon alfa-2b for chronic hepatitis C: Effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. J Hepatol 23:487-496, 1995
3. 2b for 60 weeks. Hepatology 19:280-285, 1994
4. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masazawa M, Yoshihara H, Kishida Y, Shimizu Y, Inoue A, Fusamoto H, Kamada T: Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial. Hepatology 21:291-297, 1995
5. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L: A pilot study of combination therapy with ribavirin plus interferon alfa for chronic hepatitis C. Gastroenterology 107:812-817, 1994
6. Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, Omata M: A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 20:558-564, 1994
7. Beloqui O, Prieto J, Suarez M, Gil B, Qiuan CH, Garcia N, Civeira MP: N-Acetyl cysteine enhances the response to interferon-α in chronic hepatitis C: A pilot study. J Interferon Res 13:279-282, 1993
8. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, and the Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 321:1501-1506, 1989
9. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamon JP: Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France. Hepatology 13:393-397, 1991
10. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, Benvegnù L, Casarin C, Alberti A, and the TriVeneto Viral Hepatitis Group: Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. Hepatology 22:700-706, 1995
11. Bellary S, Smith DG, Bankes P, Harris A, Shayiq R, Black M: High dose interferon α-2b therapy for chronic hepatitis C: An open label study of the response and predictors of response. Am J Gastroenterol 90:259-262, 1995
12. Caporaso N, Suozzo R, Morisco F, D'Antonio M, Romano M, Coltorti M: Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year. Ital J Gastroenterol 25:482-486, 1993
13. De Bac C, Grimaldi F, Clementi C, Duca F, Livoli D, Taliani G: Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C. Gut 34(suppl 2):S135, 1993
14. Picciotto A, Callea F, Varagona G, Bardellini E, Borzone S, De Conca V, Vallarino E, Giudici-Cipriani A, Vitali A, Grasso A, Palombino MA, Dodero M, Marenco G, Menardo G, Celle G: Lymphoblastoid interferon therapy in chronic hepatitis C: Biochemical, virological and histological evaluation of two different doses. Liver 15:20-24, 1995
15. Fong TL, Morgan TR, Phan CG, Hoefs JC: Raising the dose of interferon does not improve the response in chronic hepatitis C. J Clin Gastroenterol 20:42-44, 1995
16. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S: Treatment of chronic hepatitis C with high-dose interferon α-2b. A multicenter study. Dig Dis Sci 38:612-618, 1993
17. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, Degott C, Erlinger S, Benhamou JP: Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 109:156-165, 1995
18. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506-1510, 1989
19. Lindsay KL, Davis GL, Schiff E, Bodenheimer H, Balart L, Dienstag J, Perillo R, Tamburro C, Silva M, Goff C, Everson G, Sanghvi B, Albrecht J: Long-term response to higher doses of interferon (IFN) alfa-2b treatment of patients with chronic hepatitis C: A randomized multicenter trial. Hepatology 18(4 Pt 2):106A, 1993 (abstract)
20. Ferenci P, Vogel W, Pristautz, H, Deimer J, Denk H, Judmayer G, Maier K-P, Krejs GJ, Gangl A: One-year treatment of chronic non-A non-B hepatitis with interferon alfa-2b. J Hepatol 11(suppl 1):S50-S53, 1990
21. Ferenci P, Vogel W, Hentschel E, Pristautz H, Fiedler R, Judmaier G, Krejs GJ, Gangl A: One year interferon alpha (IFN-α) treatment of chronic hepatitis NANB. Hepatology 14(4 Pt 2):72A, 1991 (abstract)
22. Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH: A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16:649-654, 1992
23. Schalm SW: Combination therapy interferon and ribavirin: Naive patients/relapse nonresponders. In Proceedings of the Chronic HCV Infection: Public Health Threat and Emerging Consensus Symposium. Vienna, October 27-28, 1995, P46 (abstract)